Investors Pour $55M Into Diabetes-Focused Biotech Fractyl

Law360 (August 7, 2020, 5:25 PM EDT) -- Fractyl Laboratories Inc., a life sciences company focused on developing treatments for metabolic diseases including Type 2 diabetes, said Friday that it has secured $55 million in funding from a group of investors led by Taiwania Capital Management Corp.

The first close of Fractyl's Series E fundraising round represents Taiwania Capital's first investment in Fractyl; other first-time investors that contributed to the round include Catalio Capital Management, CDIB Venture Capital Corp. and YJ Capital. It also included participation from existing investors like Bessemer Venture Partners, General Catalyst, Domain Associates, Mithril Capital Management, Emergent Medical Partners, True Ventures and GV, according to...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!